Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a hold rating in a report issued on Tuesday morning.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Friday, August 16th.

Galectin Therapeutics Trading Up 1.1 %

Shares of NASDAQ GALT opened at $2.66 on Tuesday. The stock has a market capitalization of $165.31 million, a PE ratio of -3.59 and a beta of 0.61. The stock has a fifty day simple moving average of $2.57 and a 200-day simple moving average of $2.73. Galectin Therapeutics has a twelve month low of $1.55 and a twelve month high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). On average, equities analysts predict that Galectin Therapeutics will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Galectin Therapeutics

Several institutional investors have recently added to or reduced their stakes in GALT. Vanguard Group Inc. grew its holdings in shares of Galectin Therapeutics by 2.0% during the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after purchasing an additional 38,037 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after buying an additional 367,610 shares during the last quarter. Retirement Guys Formula LLC grew its stake in Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after buying an additional 12,232 shares during the last quarter. Wealthspire Advisors LLC lifted its stake in Galectin Therapeutics by 116.7% in the first quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after buying an additional 214,512 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in Galectin Therapeutics by 75.4% in the second quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock valued at $190,000 after buying an additional 36,139 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.